Manipulation of B-cell responses with histone deacetylase inhibitors

Nature Communications

Volumn 6, Issue , 2015, Pages

  Waibel, Michaela ^a,b   Christiansen, Ailsa J ^a,b   Hibbs, Margaret L ^c   Shortt, Jake ^a,b,d,e   Jones, Sarah A ^d   Simpson, Ian ^e   Light, Amanda ^f   O'Donnell, Kristy ^f   Morand, Eric F ^d   Tarlinton, David M ^f   Johnstone, Ricky W ^a,b   Hawkins, Edwin D ^a,b,g  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e MONASH MEDICAL CENTRE   (Australia)

^f WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; PANOBINOSTAT; ROMIDEPSIN; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ANTIBODY; DISEASE TREATMENT; ENZYME ACTIVITY; HEMATOLOGY; IMMUNE RESPONSE; IMMUNE SYSTEM; INHIBITOR; PROTEIN; RODENT; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SECRETING CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CD8+ T LYMPHOCYTE; CELL DIVISION; CELL MANIPULATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CROSS LINKING; FEMALE; FLOW CYTOMETRY; GERMINAL CENTER; HUMORAL IMMUNITY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MEMORY CELL; MOUSE; NONHUMAN; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGICAL MEMORY; LUPUS ERYTHEMATOSUS, SYSTEMIC;

MUS;

ANIMALS; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; FEMALE; GERMINAL CENTER; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; IMMUNOLOGIC MEMORY; INDOLES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE, INBRED C57BL;

EID: 84928974764     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7838     Document Type: Article

References (61)

1. Jacob, J., Kassir, R. & Kelsoe, G. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations. J. Exp. Med. 173, 1165-1175 (1991).
2. Liu, Y. J., Zhang, J., Lane, P. J., Chan, E. Y. & MacLennan, I. C. Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur. J. Immunol. 21, 2951-2962 (1991).
3. Inamine, A. et al. Two waves of memory B-cell generation in the primary immune response. Int. Immunol. 17, 581-589 (2005).
4. Ho, F., Lortan, J. E., MacLennan, I. C. & Khan, M. Distinct short-lived and long-lived antibody-producing cell populations. Eur. J. Immunol. 16, 1297-1301 (1986).
5. Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C. & Croce, C. M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226, 1097-1099 (1984).
6. Dalla-Favera, R. et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl Acad. Sci. USA 79, 7824-7827 (1982).
7. Taub, R. et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc. Natl Acad. Sci. USA 79, 7837-7841 (1982).
8. Ye, B. H. et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262, 747-750 (1993).
9. Goodnow, C. C. et al. Self-tolerance checkpoints in B lymphocyte development. Adv. Immunol. 59, 279-368 (1995).
10. Tsubata, T. B cell abnormality and autoimmune disorders. Autoimmunity 38, 331-337 (2005).
11. Kono, D. H. & Theofilopoulos, A. N. Genetics of SLE in mice. Springer Semin. Immunopathol. 28, 83-96 (2006).
12. Lopez-Granados, E. Epigenetic control of lymphocyte differentiation. Adv. Exp. Med. Biol. 711, 26-35 (2011).
13. Wilson, C. B., Rowell, E. & Sekimata, M. Epigenetic control of T-helper-cell differentiation. Nat. Rev. Immunol. 9, 91-105 (2009).
14. Lagger, G. et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21, 2672-2681 (2002).
15. Wilting, R. H. et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J. 29, 2586-2597 (2010).
16. Yamaguchi, T. et al. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev. 24, 455-469 (2010).
17. Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769-784 (2006).
18. Dickinson, M., Johnstone, R. W. & Prince, H. M. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest. New Drugs 28(Suppl 1): S3-S20 (2010).
19. Chesi, M. et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 120, 376-385 (2012).
20. Lindemann, R. K. et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc. Natl Acad. Sci. USA 104, 8071-8076 (2007).
21. Moreira, J. M., Scheipers, P. & Sorensen, P. The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 3, 30 (2003).
22. West, A. C. et al. An intact immune system is required for the anti-cancer activities of histone deacetylase inhibitors. Cancer Res. 73, 7265-7276 (2013).
23. Tao, R. et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13, 1299-1307 (2007).
24. Lu, Z. P., Ju, Z. L., Shi, G. Y., Zhang, J. W. & Sun, J. Histone deacetylase inhibitor Trichostatin A reduces anti-DNA autoantibody production and represses IgH gene transcription. Biochem. Biophys. Res. Commun. 330, 204-209 (2005).
25. Mishra, N., Reilly, C. M., Brown, D. R., Ruiz, P. & Gilkeson, G. S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 111, 539-552 (2003).
26. Sweet, M. J., Shakespear, M. R., Kamal, N. A. & Fairlie, D. P. HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation. Immunol. Cell. Biol. 90, 14-22 (2012).
27. Reilly, C. M., Regna, N. & Mishra, N. HDAC inhibition in lupus models. Mol. Med. 17, 417-425 (2011).
28. Hancock, W. W., Akimova, T., Beier, U. H., Liu, Y. & Wang, L. HDAC inhibitor therapy in autoimmunity and transplantation. Ann. Rheum. Dis. 71(Suppl 2): i46-i54 (2012).
29. Hawkins, E. D. et al. Measuring lymphocyte proliferation, survival and differentiation using CFSE time-series data. Nat. Protoc. 2, 2057-2067 (2007).
30. Hawkins, E. D., Turner, M. L., Dowling, M. R., van Gend, C. & Hodgkin, P. D. A model of immune regulation as a consequence of randomized lymphocyte division and death times. Proc. Natl Acad. Sci. USA 104, 5032-5037 (2007).
31. Hawkins, E. D. et al. Quantal and graded stimulation of B lymphocytes as alternative strategies for regulating adaptive immune responses. Nat. Commun. 4, 2406 (2013).
32. Turner, M. L., Hawkins, E. D. & Hodgkin, P. D. Quantitative regulation of B cell division destiny by signal strength. J. Immunol. 181, 374-382 (2008).
33. Rush, J. S. & Hodgkin, P. D. B cells activated via CD40 and IL-4 undergo a division burst but require continued stimulation to maintain division, survival and differentiation. Eur. J. Immunol. 31, 1150-1159 (2001).
34. Insinga, A. et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 11, 71-76 (2005).
35. Li, N. et al. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc. Natl Acad. Sci. USA 105, 4796-4801 (2008).
36. Wang, D. et al. LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice. Biol. Blood Marrow Transplant. 18, 1182-1190 e1181 (2012).
37. Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A. & Nagata, S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314-317 (1992).
38. Matthews, G. M. et al. Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk∗MYC multiple myeloma. Cell Death Dis. 4, e798 (2013).
39. Richardson, P. G. et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomibrefractory myeloma. Blood 122, 2331-2337 (2013).
40. Xu, Y., Harder, K. W., Huntington, N. D., Hibbs, M. L. & Tarlinton, D. M. Lyn tyrosine kinase: accentuating the positive and the negative. Immunity 22, 9-18 (2005).
41. Chan, V. W., Meng, F., Soriano, P., DeFranco, A. L. & Lowell, C. A. Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity 7, 69-81 (1997).
42. Hibbs, M. L. et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 83, 301-311 (1995).
43. Nishizumi, H. et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity 3, 549-560 (1995).
44. Carrington, E. M. et al. BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proc. Natl Acad. Sci. USA 107, 10967-10971 (2010).
45. Luzina, I. G. et al. Spontaneous formation of germinal centers in autoimmune mice. J. Leukoc. Biol. 70, 578-584 (2001).
46. Wang, L., Tao, R. & Hancock, W. W. Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance. Immunol. Cell. Biol. 87, 195-202 (2009).
47. Bantscheff, M. et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255-265 (2011).
48. Peart, M. J. et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 3697-3702 (2005).
49. Newbold, A. et al. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol. Cancer Ther. 7, 1066-1079 (2008).
50. Tsao, B. P. The genetics of human systemic lupus erythematosus. Trends Immunol. 24, 595-602 (2003).
51. Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222-233 (2010).
52. Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64, 1215-1226 (2012).
53. Bolden, J. E. et al. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis. 4, e519 (2013).
54. Vikstrom, I. et al. Mcl-1 is essential for germinal center formation and B cell memory. Science 330, 1095-1099 (2010).
55. Deangelo, D. J. et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 27, 1628-1636 (2013).
56. Cohen, P. L. & Eisenberg, R. A. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9, 243-269 (1991).
57. Tsantikos, E. et al. Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6. J. Immunol. 184, 1348-1360 (2010).
58. Smith, K. G., Light, A., Nossal, G. J. & Tarlinton, D. M. The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response. EMBO J. 16, 2996-3006 (1997).
59. Smith, K. G. et al. bcl-2 transgene expression inhibits apoptosis in the germinal center and reveals differences in the selection of memory B cells and bone marrow antibody-forming cells. J. Exp. Med. 191, 475-484 (2000).
60. Hawkins, E. D. et al. Regulation of asymmetric cell division and polarity by Scribble is not required for humoral immunity. Nat. Commun. 4, 1801 (2013).
61. Austin, III H. A. et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 25, 689-695 (1984).